Qiagen enters the T-cell testing fray
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
Covid-19 oils the wheels of business development
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
Poor fourth quarter mars strong year for medtech floats
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Few medtechs go public, but those that do, do nicely
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
